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Autoantibodies (ETiCS) Study 
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University Hospital of Würzburg, Department of Internal Medicine I, Cardiology, 
Comprehensive Heart Failure Centre CHFC/IFB, Würzburg,  
Germany 
1. Introduction 
Progressive cardiac dilatation and pump failure of unknown aetiology - termed “idiopathic” 
dilated cardiomyopathy (DCM) (Richardson et al., 1996; Maron et al., 2006) - represents one 
of the main causes of severe heart failure in Western populations with an annual incidence 
of about 100 and a prevalence of 300-400 patients per year (American Heart Association, 
2009). The large majority of cases are thought to arise from an initial (mostly viral) infection 
leading to acute myocardial inflammation. Acute myocarditis may either heal (about one 
third of the cases) or progress to a chronic inflammatory process with continued fibrotic 
repair, subsequent dilatation of the left and/or right ventricle and –finally– severe 
congestive heart failure (about another third of the patients). Progression to DCM appears to 
occur particularly, when associated (a) with chronic inflammation of the myocardium due to 
viral persistence (Kühl et al., 2005) and/or (b) with the development of autoantibodies 
directed against distinct sarcoplasmatic or myocyte membrane proteins that are essential for 
cardiac function (Freedman & Lefkowitz, 2004; Jahns et al., 2006). The latter findings are 
further strengthened by the fact that patients with DCM often have alterations in both, their 
innate and their adaptive immune system (Limas, 1997; Luppi et al., 1998; Jahns et al., 2006; 
Mahrholdt et al., 2006). Thus, under certain conditions an initial acute inflammatory reaction 
may proceed into a kind of low-grade inflammation (MacLellan & Lusis, 2003) facilitating 
the development of abnormal or misled immune responses to the primary (infectious) 
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trigger (MacLellan & Lusis, 2003; Freedman & Lefkowitz, 2004; Kühl et al., 2005; Smulski et 
al., 2006; Maekawa et al., 2007). More recently, a detailed molecular analysis of T cell 
infiltrates in  human endomyocardial biopsies (EMBs) from both, patients with acute 
myocarditis and patients with (post-)inflammatory DCM revealed an increased expression 
of CD3d, CD3z, and T cell receptor beta constant region (TRBC) in both disease entities. 
However, differential expression of functional T cell markers was found in DCM EMBs only 
(dominance of Th1 markers, regulatory [FoxP3] T cells, and cytotoxic T cells (CTLs)) and not 
in acute myocarditis. Additionally, in DCM EMBs some Th2 marker genes were increased, 
indicating that a Th2 response (required for T/B cell interactions) also participates in the T 
cell infiltrates in DCM (Noutsias et al., 2011). This might explain, why a substantial number 
of DCM patients have been found to develop cross-reacting antibodies and/or 
autoantibodies to different cardiac self-antigens, including mitochondrial proteins (e.g., 
adenine nucleotide translocator, lipoamide and pyruvate dehydrogenase (Schultheiss & 
Bolte, 1985; Schultheiss et al., 1988; Pohlner et al., 1997; Schulze et al., 1999)), sarcoplasmatic 
proteins (e.g., actin, laminin, myosin, troponin (Neumann et al., 1990; Caforio et al., 2002; 
Okazaki et al., 2003; Göser et al., 2006; Li et al., 2006)), and membrane proteins (e.g., cell 
surface adrenergic or muscarinergic receptors (Fu, L.X.M. et al., 1993; Magnusson et al., 
1994; Jahns et al., 1999; Christ et al., 2006)).  
Irrespective of whether development of DCM is primarily due to chronic myocardial 
infection (Kühl et al., 1996) or to abnormalities in the adaptive or innate immune system 
(Luppi et al., 1998; Eriksson et al., 2003), in both cases cardiac tissue injury is believed to be 
mediated mainly by cytokines and/or heart-specific autoantibodies (Caforio et al., 1995; 
Limas, 1997; Eriksson et al., 2003). However, the pathophysiological relevance of each of the 
aforementioned cardiac autoantibodies (aabs) is far from clear. Low titers of autoantibodies 
to various house-keeping antigens can also be detected in healthy subjects as a part of the 
natural immunological repertoire (Rose, 2001).  
In addition, under physiological conditions at least the intracellularly localized cardiac 
antigens are not easily accessible for the immune system. Thus, the mechanisms by which 
autoimmune-mediated myocardial injury is initiated are mostly based on indirect or 
circumstantial evidence (Limas, 1997). The potential pathophysiological - and thus clinical – 
relevance of a heart-specific autoantibody depends on its disease-inducing or -aggravating 
potential, which in turn is supposed to be associated with both the accessibility and the 
functional relevance of its target. Therefore, autoantibodies directed against cell surface key 
constituents, and in particular aabs that have the potential to affect myocardial contraction 
and relaxation (e.g. , by interaction with the cardiac beta1-adrenoceptor (beta1-AR)) and/or 
the M2-muscarinic acetylcholine receptor (M2-AchR)) represent key candidates involved in 
the initiation and/or progression of DCM (Fu et al. 1993, 2008; Magnusson et al., 1996; 
Limas, 1997; Engelhardt et al., 2004; Jahns et al., 2004; Freedman & Lefkowitz, 2004). 
Whereas anti-muscarinic antibodies (exhibiting an agonist-like effect on cardiac M2-AchR) 
have been associated with negative chronotropic effects at the sinuatrial level (e.g., sinus 
node dysfunction, atrial fibrillation (Wang et al., 1996; Baba et al., 2004)), functionally 
activating anti-beta1-AR antibodies have been associated with both the occurrence of severe 
arrhythmias at the ventricular level, and the development of (maladaptive) left ventricular 
hypertrophy, finally switching to left ventricular enlargement and progressive heart failure 
(Jahns et al., 1999, 2006; Iwata et al., 2001; Engelhardt et al., 2004; Störk et al., 2006). In 
addition, both autoantibodies seem to target the (easily accessible) second extracellular loop 
of the respective receptors.  
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To generate an autoimmune response, myocyte membrane proteins (including receptors) 
must be degraded to small oligopeptides able to form a complex with a major 
histocompatibility (MHC) class II or human leukocyte antigen (HLA) molecule of the host 
(Hoebeke et al., 1996). In previous clinical studies autoimmunity has been found to be 
associated with certain HLA- and MHC class II-phenotypes (Limas, 1996), and also with the 
expression and/or activity of the T-lymphocyte antigen 4 (CTLA-4) - known as a potent 
(indirect) suppressor of the immune system (Golden et al., 2005). Therefore, another 
important point to consider in the development of (human) post-inflammatory and/or post-
ischemic cardiomyopathy is the patients’ genetic pre-disposition, which will determine 
both, the susceptibility to self-directed immune reactions and the phenotypic expression of 
the myocardial disease (MacLellan & Lusis, 2003; Limas et al., 2004).  
On this background the following book-chapter will review current knowledge and recent 
experimental and clinical evidence for the potential role of cardiac autoantibodies in the 
pathogenesis of DCM focussing on the rationale and expected insights from the prospective 
diagnostic multicentre Etiology, Titre-Course, and (effect on) Survival of cardiac 
autoantibodies (ETiCS) study. 
2. Rationale and scope of the ETiCS study 
Evidence for a pathophysiologic role of autoimmunity in human heart disease has 
substantially increased during the past two decades, but the true prevalence and clinical 
impact of cardiac autoantibodies (aabs) in human heart disease are still unclear, as are the 
events leading to their formation, their frequency of appearance, and their kinetics (that is, 
their patterns of clearance and/or persistence).  
In this regard, the investigator-initiated diagnostic multicentre ETiCS study will 
prospectively address the hypothesis that a first inflammatory (i.e., acute myocarditis 
(AMitis)) or ischemic injury of the myocardium (i.e., first acute myocardial infarction 
(FAMI)) may trigger the development of heart-directed autoimmune reactions (Fig. 1). 
  
 
Fig. 1. Formation of autoantibodies against myocardial self-antigens.  
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Immunogenicity is defined as the property of a molecule to induce an immune response 
(Hoebeke, 1996). To serve as a potential antigen, myocyte constituents (e.g., cardiac 
membrane receptors) must be degraded by proteolysis into small fragments (oligopeptides), 
and one or several of the generated fragments must be able to form a complex with one of 
the major histocompatibility complexes (class II-MHCs) or human leukocyte antigen (HLA) 
molecules of the host. When presented to T cells (Harding et al., 1990; Mobini et al., 1999) 
antigenic parts of such myocyte-derived (self) peptides may engender an immunological 
response. Acute inflammatory processes are supposed to enhance the occurence of self-
directed immune responses (e.g., acute viral or bacterial myocarditis and/or acute ischemic 
events (Borda et al., 1984; Latif et al., 1993; Kühl et al., 1996; Limas, 1997; Noutsias et al., 
1999; Liu & Mason, 2001; Rose, 2001; Caforio et al., 2002)). 
Therefore, we assume that a first substantial inflammatory or ischemic myocyte damage – 
through liberation of a “critical amount” of cardiac self-antigens previously hidden to the 
immune system – might induce and perpetuate a disease-causing and/or -modulating 
autoimmune reaction that deteriorates cardiac function and ultimately results in progressive 
heart failure.  
As a consequence, the ETiCS study has been designed to provide a maximum of sequential 
clinical and serological data from patients after a first inflammatory or ischemic cardiac 
event. The development/prevalence and titre-course (clearance/persistence) of distinct 
cardiac aabs after 0, 3, 6, and 12 months of either event will be prospectively assessed and 
correlated with the corresponding cardiac functional parameters, cardiac imaging 
(echocardiography, cardiac magnetic resonance imaging), and clinical outcome. A limited 
number of ETiCS sub-studies will focus on components of the patients’ immune system 
potentially involved in the generation of cardiac receptor-aabs – including a search for pre-
disposing genotypes (Limas et al., 2004; Caforio & Iliceto, 2008) – and on the possible impact 
of conformational adrenoceptor-aabs on renal function (Boivin et al., 2001).  
Expanding the scope of ETiCS beyond adrenoceptor-directed autoimmunity other known 
cardiac aabs will be investigated by the respective expert core centres, including aabs 
against the muscarinic acetylcholine receptor 2 (Fu, L.X.M. et al., 1993), against troponin I 
(Göser et al., 2006), organ-specific and skeletal muscle cross-reactive anti-heart-aabs (Caforio 
et al., 2007), and cardio-depressant aabs (Felix et al., 2002). This joint venture will enable a 
comprehensive characterisation of heart-directed autoimmunity after inflammatory or 
ischemic disruption of myocardial integrity, and allow for cross-correlations of the titre-
course and prognostic impact of all cardiac aabs prospectively analyzed.   
3. Design of the ETiCS study 
The prospective ETiCS study complies with the standards of Good Clinical Practice (GCP) 
and has been approved by the Ethics committees of all participating institutions. Within a 
two years-period ETiCS will include 400 patients with a first cardiac event, 200 of them with 
acute myocarditis (AMitis), and 200 patients with a first myocardial infarction (FAMI; acute 
ST-elevation MI only, without any history or signs of previous myocardial infarction). After 
inclusion and baseline assessment, the patients will undergo three follow-up visits after 3, 6, 
and 12 months (Fig. 2). Diagnosis of acute myocarditis is based on at least one major and 
two minor clinical criteria and/or symptoms (see table 1) and must be confirmed by 
endomyocardial biopsy (EMB) using either the WHO/ISFC (Richardson et al., 1996; Elliott 
et al., 2008) or the Dallas criteria (Aretz et al., 1987). This proceeding is in full accordance 
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with the actual AHA/ACC/ESC scientific statement on the role of EMB in the management 
of cardiovascular disease (Cooper et al., 2007), which strongly recommends EMB in acute 
myocarditis because of its potential relevance for outcome and therapeutic decisions 
(Kindermann et al., 2008; Frustaci et al., 2009). In addition, immunohistology and molecular 
analysis of the EMBs may also significantly contribute to further elucidate the clinical 
impact of heart-directed autoimmune reactions.  
 
Suspicion of acute myocarditis  
(One major and two minor criteria fulfilled) 
Major criteria 
ST/T wave changes in the electrocardiograms (ECG) 
Ventricular arrhythmia (ECG) 
Pericardial effusion on echocardiography 
Impairment of LVEF on echocardiography with CAD excluded by coronary 
angiography (no stenosis >50%) 
 
Minor criteria 
Dyspnea, new onset within the past 30 days 
Chest pain, new onset within the past 30 days 
Palpitations, new onset within the past 30 days 
History of infection within the past 30 days 
Fever >38.0° C within the past 30 days 
 
Table 1. Diagnostic criteria for suspicion of acute myocarditis. 
 
 
Fig. 2. Time schedule of the follow-up examinations in the ETiCS study.  
Echocardiography and cardiac magnetic resonance imaging (cMRI) will be carried out in all 
patients within 24 to 96 hours of hospitalisation and one year after the respective cardiac 
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event. Follow-up visits at 3, 6, and 12 months comprise a detailed patient history including 
medication, physical examination, a standardized health questionnaire, echocardiography, 
ECG, Holter-ECG, and blood sampling (Fig. 2). The sequentially obtained blood samples 
will serve to determine the time course of formation and the titre-course 
(clearance/persistence) of distinct cardiac aabs at 0, 3, 6, and 12 months after inflammatory 
or ischemic cardiac injury (AMitis, FAMI). Three-hundred healthy subjects with normal 
blood pressure, ECG, and exercise-stress test will serve as a control collective (male to 
female ratio 1:1, n=50 per five-years age range, no history of myocardial infarction, diabetes, 
or peripheral vascular disease). The primary endpoint of the planned cross-sectional 
analyses is the association of a specific cardiac aab status at diagnosis (aab-positive/aab-
negative) with (a) the change in cardiac function as derived from sequential 
echocardiograms and cMRI (baseline versus 12 months), and (b) the severity and clinical 
course of the index disease. Longitudinal primary endpoints are titre-changes of a given 
cardiac aab over time, conversion rates (persistence/clearance), and the “time to first 
cardiovascular event” (see table 2 for definition of composite endpoints). Pre-specified 
secondary endpoints for each of the different cardiac aabs at diagnosis are time to 
cardiovascular death and time to all-cause death (table 2).  
 
Primary endpoint: prospective ETiCS study 
 Titre course of conformational cardiac aabs 
Secondary endpoints: prospective ETiCS study 
 Change in left ventricular enddiastolic diameter 
 Change in left ventricular ejection fraction 
 Occurrence of ventricular arrhythmias 
 Change of clinical NYHA classification 
 Severity of inflammation as assessed by EMB/cMRI 
 Time to cardiovascular death/all-cause death 
Composite endpoints  
 Cardiovascular Death 
 Myocardial infarction 
 Resuscitation (successful or not successful) 
 ICD discharge, if appropriate 
 Cardiac transplantation 
 Sudden cardiac death 
 Death due to progressive heart failure 
 Death due to myocardial infarction 
Table 2. Pre-defined endpoints of the ETiCS study. 
4. ETiCS substudies  
4.1 Immunobiology of heart-directed autoreactivity 
This substudy attempts to unravel the step-by-step changes occurring in a patients’ immune 
system whilst autoantibody-mediated immune cardiomyopathy develops after 
inflammatory or ischemic myocardial injury, including the time course and cell types (T and 
B cell subpopulations) involved in the generation of cardiac aabs. The reactivity and 
prevalence of receptor (auto)antigen-specific T and B cell populations will be assessed by 
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antigenic recall assays as well as FACS and Elispot analyses. In addition, the respectively 
activated immunologic paths will be derived from the Th1/Th2/Th17 cytokine profiles 
determined in the sera from cardiac autoantibody-positive patients with acute myocarditis 
(including an analysis of the corresponding EMBs (Noutsias et al, 2011)) or acute transmural 
myocardial infarction. Since the cytotoxic T-lymphocyte antigen 4 (CTLA-4) is a potent 
(indirect) suppressor of the immune system, its mutation or hampered expression might 
promote hyperreactivity to autoantigens (Golden et al., 2005). Thus, in all ETiCS patients 
CTLA-4 expression and CTLA-4 alleles will be determined by FACS and by PCR, 
respectively. In addition, in all patients the HLA-DR/DQ and MHC class II haplotypes 
(Limas et al., 2004; Caforio & Iliceto, 2008) will be determined and correlated with the 
formation and titre-course of distinct cardiac aabs in order to unravel the individual genetic 
susceptibility for heart-directed autoimmune reactions. 
4.2 Adrenoceptor-autoantibodies and their impact on kidney function 
The possible clinical implications of adrenoceptor-directed autoimmunity have gained 
increasing interest in human heart disease. By contrast, the renal effects of functionally 
active adrenoceptor-aabs have been almost neglected. Previous immuno-histologic studies 
on the rat kidney strongly suggest that functionally stimulating adrenoceptor aabs are 
capable of modulating the secretion of renin from the juxtaglomerular cells via renal beta1-
AR and, also, to increase the sodium-reabsorption in the distal tubulus (Boivin et al., 2001). 
Thus, through renal beta1-AR-mediated activation of the renin-angiotensin-aldosterone-
system (RAAS) and/or augmentation of the circulating blood volume  such aabs might 
contribute to further worsening of the prognosis of antibody-positive heart failure patients.  
To assess the impact of adrenoceptor-aabs on kidney function (and clinical outcome), a 
number of pre-specified renal functional parameters will be sequentially determined in all 
ETiCS patients (e.g. serum versus urine creatinine/sodium/pH; glomerular filtration rate 
(GFR), urinary protein excretion). Primary endpoints are the relationship between antibody-
titres and renal function at baseline and the “time to first cardiovascular event”, adjusted for 
renal function. Secondary endpoints include the change in renal function dependent on the 
formation and conversion rates (clearance/persistence) of adrenoceptor-aabs.  
These data might furnish a rationale for the development of novel therapeutic strategies to 
protect the kidney(s) from functional adrenoceptor-aabs in aab-positive heart failure 
patients. 
5. Conclusion and expected insights from the ETiCS study 
In the last two decades, much knowledge has accumulated with respect to the possible 
pathophysiologic and clinical implications of heart-directed aabs (Jahns et al., 2006; Fu, M., 
2008).  
Homologies between cardiomyocyte surface molecules (in particular membrane receptors) 
and viral or bacterial proteins have been proposed as a mechanism for the elaboration of 
endogenous cardiac autoantibodies by antigen mimicry (Elies et al., 1996; Hoebeke et al., 
1996). Chagas’ heart disease, a slowly evolving inflammatory cardiomyopathy, is one of the 
best investigated examples to highlight this mechanism. The disease is induced by the 
protozoon Trypanosoma cruzi. About 30% of the Chagas’ patients develop antibodies that 
cross-react between the ribosomal P2beta-protein of T. cruzi and some specific amino acids 
present in the second extracellular loop of the human beta1-adrenoceptor (Elies et al., 1996). 
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Because the large majority of functionally active beta1-aabs detected in DCM patients seem 
to be directed against the same receptor loop, it was speculated that these antibodies might 
also originate from molecular mimicry between the beta1-adrenoceptor and hitherto non-
identified viral pathogen (Hoebeke, 1996). Another example is Chlamydia–associated heart 
disease, which in BALBc mice appears to be induced by antigen mimicry between 
Chlamydia antigens and the alpha-myosin heavy chain molecule, resulting in activation of 
autoreactive T- and B-cells (Bachmaier et al., 1999).  
However, irrespective of (potentially occurring) immunologic cross-reactions, to date no 
prospective clinical study has ever addressed the key question, whether structural damage 
to the heart muscle (e.g., necrosis or apoptosis) is a mandatory pre-requisite for the 
formation of heart-directed aabs.  
In general, the immune system will not attack cardiac self-proteins. On a susceptible genetic 
background, however, this self-inhibition of immune effector cells after cardiac injury may 
be hampered. It is presently unclear, whether this autoreactivity depends on the kind and 
extent of injury, the kind and amount (or “dose”) of self-antigens presented, or the kind and 
quality of the subsequently engaged immunologic paths. Regarding the latter aspect, a 
recent analysis of the expression of functional T cell markers in EMBs from patients with 
acute myocarditis and patients with chronic (post-inflammatory) DCM found an increased 
expression of CD3d, CD3z, and TRBC in both disease entities, whereas Th1 (more than) Th2 
marker-genes as well as regulatory and cytotoxic T cells were differentially up-regulated in 
DCM EMBs only (Noutsias et al., 2011). Interestingly, in human DCM biopsies any clues for 
a Th17 response were lacking, which is in sharp contrast to findings in murine models of 
(experimental) autoimmune myocarditis (Valaperti et al., 2008). Nevertheless, from these 
recent molecular data it seems clear now that in human DCM a Th2 response also 
participates in the myocardial T cell infiltrates and serves as a pre-requisite for the 
stimulation (that is, maturation) of autoreactive B cells that, e.g., produce cardiac 
autoantibodies. 
In acute myocarditis diffuse and/or focal inflammation causes structural damage to the 
heart. If myocardial inflammation persists, in a majority of cases cardiac function does not 
recover and finally may result in severe DCM. Acute ischemia also causes structural damage 
to the heart and to date represents the most common aetiology of heart failure. Thus, a 
structured follow up of patients with either disease is both pathophysiologically and 
clinically relevant.  
The ETiCS study will follow such patients 3, 6, and 12 months after their index events, 
because the formation of autoreactive immunoglobulin G (IgG) is supposed to take place 
within the first 6 weeks (up to three months) after the index event. 
A variety of autoreactive IgG have been identified, but only few of them have been 
investigated more in detail. Because myocyte surface receptors are easily accessible to 
circulating autoantibodies, the cardiac beta1-adrenergic receptor (which is the predominant 
adrenocepter subtype in the heart) and the M2-muscarinic acetylcholine receptor represent 
key targets for autoreactive antibodies that might affect heart function to some extent. 
To generate an autoimmune response, membrane receptors must be degraded to small 
oligopeptides able to form a complex with a MHC class II or HLA molecule of the host 
(Hoebeke, 1996). In case of the human beta1-adrenoceptor, a computer-based search for 
potential immunogenic amino-acid streches within this (seven) transmembrane spanning 
protein revealed, that the only portion of the molecule containing B- and T-cell epitopes 
(and accessible to antibodies) was in fact the predicted second extracellular receptor loop 
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(beta1-ECII). This might explain the successful use of ECII-mimicking peptides for the 
induction of specific anti-beta1-ECII antibodies in different animal-models (Magnusson et 
al., 1996; Jahns et al., 2004, 2006). Finally, by isogenic transfer of anti-beta1-ECII antibodies in 
a human-analogous rat model the (autoimmune-)attack against the hearts of healthy 
recipients by activating anti-beta1-antibodies has been identified as a possible cause of heart 
failure (Jahns et al., 2004).  
In the last decade several research groups have independently shown that anti-beta1-ECII-
antibodies preferentially recognize native membrane beta1-receptors in various 
immunological assays (cell-ELISA, immunoprecipitation, immunofluorescence), indicating 
that such antibodies or autoantibodies are conformational (Jahns et al., 1999, 2006; Fu 2008). 
In addition, functional tests revealed that such anti-beta1-ECII may also act as allosteric 
regulators of beta1-adrenoceptor activity through modulation of cellular cAMP-production 
and/or cAMP-dependent protein kinase (PKA) activity (Wallukat et al., 1991; Limas et al., 
1992; Jahns et al., 1999; Nikolaev et al., 2007). The use of different screening-techniques 
renders direct comparisons of the available data difficult, however. Hence, so far reported 
prevalences should be always interpreted in the context of the detection method utilised. 
Nevertheless, taken all these reports together, there is wide consent that a substantial 
fraction of patients with DCM and ICM, but only very few healthy subjects have ciculating 
functionally active adrenoceptor-aabs (Wallukat et al., 1991; Magnusson et al., 1994; Jahns et 
al., 1999). An association of such aabs with impaired cardiac function (Jahns et al., 1999), a 
higher incidence of ventricular arrhythmias (Iwata et al., 2001; Störk et al., 2006), and a 
higher incidence of sudden cardiac death (Iwata et al., 2001) have been demonstrated. In 
addition, a previous clinical follow-up study also implies an increased risk for 
(cardiovascular) mortality in adrenoceptor aab-positive DCM patients (Störk et al., 2006).  
To further analyse the time-course and sequentially engaged immunologic processes in 
autoimmune-mediated heart disease, the ETiCS study will prospectively follow the 
evolution of cardiac morphology and function after a first inflammatory or ischemic 
myocyte damage. In total 400 patients will benefit from a structured follow-up and best 
standard available medical care. The central hypothesis of ETiCS is that both inflammatory 
and ischemic myocardial injury may trigger a sequence of immunologic reactions which 
result in the formation of functionally active cardiac receptor-aabs (Jahns et al., 2006). Thus, 
the pre-specified primary endpoint is the titre of receptor-aabs at diagnosis compared to 3, 6, 
and 12 months after the index event. Since these aabs are thought to confer additional risk, 
pre-specified secondary endpoints of the ETiCS study comprise occurrence of life-
threatening arrhythmias, changes in cardiac diameters and function, changes in clinical 
status, time to cardiovascular death, and time to all-cause death.  
Endomyocardial biopsies will allow for a correlation of cardiac aab-titres with the severity 
of myocardial inflammation (Aretz et al., 1987; Elliott et al., 2008; Kindermann et al., 2008) , 
with the kind of T cells engaged (Th1 vs. Th2-response, Treg, CTLs (Noutias et al. 2011)), 
and with the presence and/or activity of infective agents detected (that is, the type and load 
of pre-specified viral/microbial pathogens, as determined by PCR (Kühl et al., 2005)).  
Once available, the results of the ETiCS study will significantly contribute to a number of 
important diagnostic, pathophysiologic and prognostic issues in autoantibody-mediated 
heart disease (Fu, M., 2008). We expect insights on the role of inflammatory (and ischemic) 
cardiac damage in triggering autoimmune processes (including the involved immunologic 
paths), and on the relevance of heart-directed autoimmune reactions for the initiation or 
progression of heart failure (Jahns et al., 2006). In particular, we might learn and better 
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understand whether –and if so, then to which extent– the specific target of a heart-directed 
autoantibody, but also its respective titre and biological activity and –last not least– its 
respective kinetics (that is, antibody-persistence or -clearance over time) relate to the 
complex process of cardiac wounding and healing. Different cardiac aabs might have 
distinct propensities to induce a certain cardiac phenotype, and the ETiCS study will allow 
for a differentiation of such features in a prospective manner. Thereby, additional 
prognostic markers for patients with an unfavourable course of autoimmune heart failure 
might be recognised and, as a consequence, conventional treatment modalities could be 
optimized earlier and/or novel -more specific- treatment strategies could be developed. 
6. Future perspectives and therapeutic implications 
Despite available treatment guidelines, the recent progress in conventional 
pharmacotherapy, and promising novel device-based therapeutic approaches, the outcome 
of patients suffering from heart failure remains unsatisfactory. This has stimulated the 
search for causal treatment strategies aiming to block or neutralize factors thought to play a 
role in heart failure progression.  
In a large number of neurologic, rheumatologic, and endocrine disorders autoimmune 
phenomena have been recognised as main disease-causing factors. Their relevance in human 
heart disease and failure, however, still need to be substantiated (Jahns et al., 2006; Fu, M., 
2008) although preliminary clinical data suggest that the presence of certain cardiac aabs 
clearly worsens the prognosis of patients with idiopathic DCM (Störk et al., 2006). 
Therapeutic strategies known from other autoimmune disorders, such as application of 
peptide-ligands (for multiple sclerosis (Warren et al., 2006)) or immunoadsorption of 
disease-causing aabs (for myasthenia gravis (Tzartos et al., 2008)) might thus also offer 
treatment options for a variety of human cardiac disorders.  
In this regard, recent in vitro experiments with functionally active receptor-aabs isolated 
from a smaller number of DCM-patients indicate, that aab-induced adrenoceptor activation 
might be abrogated by incubation with epitope-mimicking peptides (Nikolaev et al., 2007; 
Jahns et al. 2010). Although clinical in vivo data with epitope-derived antibody-scavengers 
are still lacking, the latter in vitro findings together with the results from the ETiCS study 
should stimulate further research in the field of specifically antibody-directed therapeutic 
strategies.  
In addition to established anti-adrenergic drugs like cardioselective beta-blockers such 
strategies might comprise (a) the aforementioned epitope-derived peptides as antibody-
scavengers (Jahns et al., 2010), (b) an elimination of functionally active cardiac aabs by 
selective or non-selective immunoadsorption (studies currently under way (Felix & Staudt, 
2008; Müller et al., 2008)), or (c) the direct targeting/suppression of autoantibody-producing 
B cells and/or plasma-cells themselves (Neubert et al., 2008).  
At least in animal models of antibody-induced immune-cardiomyopathy and –nephropathy 
some of these novel therapeutic approaches have already been successfully applied (Jahns et 
al., 2005; Matsui et al., 2006; Neubert et al., 2008; Jahns et al., 2010). Hence, the results from 
the clinical (diagnostic) ETiCS study might also furnish a basis for and accelerate further 
pre-clinical development of such novel therapeutic approaches and agents targeting at 
cardio-noxious aabs, and –hopefully– for a faster transfer into clinical practice. Moreover, by 
initiating a joint venture of the leading European research institutes in the field of cardiac 
autoimmunity, ETiCS could equally serve as a starting point for future common efforts to 
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further understand and therapeutically modulate the immune system with respect to 
immune-mediated (post-inflammatory) human cardiac disorders. 
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